# **Morphine Sulfate Compounded** Injection

## **DEFINITION**

Morphine Sulfate Compounded Injection contains NLT 90.0% and NMT 110.0% of the labeled amount of morphine sulfate pentahydrate [(C<sub>17</sub>H<sub>19</sub>NO<sub>3</sub>)<sub>2</sub>·H<sub>2</sub>SO<sub>4</sub>·

Prepare Morphine Sulfate Compounded Injection, 10 or 50 mg/mL, as follows (see Pharmaceutical Compounding— Sterile Preparations (797).

### 10-mg/mL Morphine Sulfate Compounded Injection

Morphine sulfate pentahydrate <sup>a</sup>	1 g
Sodium Chloride	760 mg
Sterile Water for Injection, a sufficient quantity to make	100 mL

 $<sup>^{\</sup>rm a}$  Morphine Sulfate, USP, is morphine sulfate pentahydrate; therefore no additional calculation is needed to account for the waters of hydration.

#### 50-mg/mL Morphine Sulfate Compounded Injection

Morphine sulfate pentahydrate <sup>a</sup>	5 g
Sodium Chloride	450 mg
Sterile Water for Injection, a sufficient quantity to make	100 mL

<sup>&</sup>lt;sup>a</sup> Morphine Sulfate, *USP*, is morphine sulfate pentahydrate; therefore no additional calculation is needed to account for the waters of hydration.

Dissolve the Morphine sulfate pentahydrate and Sodium Chloride in Sterile Water for Injection in a suitable calibrated container. Add sufficient Sterile Water for Injection to bring to final volume and mix well. Pass through a sterile filter of 0.22-µm pore size into sterile container(s).

# **ASSAY**

## Change to read:

## PROCEDURE

**Solution A:** Dissolve 5.44 g of dibasic potassium phosphate in 800 mL of water and add 200 mL of methanol.

Mobile phase: See Table 1.

Table 1

Time (min)	Methanol (%)	Solution A (%)
0.0	0	100
3.0	▲0	100 <sub>▲ (IRA 1-Sep-2019)</sub>
8.0	45	55
13.0	45	55
13.1	0	100
20.0	0	100

Standard solution: 1 mg/mL of morphine sulfate pentahydrate prepared from USP Morphine Sulfate RS in

Sample solution: Transfer 0.4 mL of the Injection into a 100-mL volumetric flask, and dilute with water to volume.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × ▲15-cm<sub>▲ (IRA 1-Sep-2019)</sub>; 5-μm packing

Flow rate: 1.0 mL/min Injection volume: 15 µL

System suitability

Sample: Standard solution

[NOTE—The retention time for morphine sulfate is

about 10.5 min.] Suitability requirements Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate

injections

**Analysis** Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of morphine sulfate pentahydrate  $[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot$ 5H<sub>2</sub>O] in the portion of Injection taken:

Result = 
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

= peak response from the Sample solution  $r_U$ = peak response from the Standard solution  $C_{S}$ 

= concentration of USP Morphine Sulfate RS in the Standard solution (mg/mL)

 $C_{U}$ = nominal concentration of morphine sulfate pentahydrate in the Sample solution (mg/mL)

Acceptance criteria: 90.0%–110.0%

# **SPECIFIC TESTS**

• **PH** (791): 2.5–6.5

• **STERILITY TESTS** (71), Test for Sterility of the Product to Be Examined, Membrane Filtration: Meets the requirements

# Change to read:

- BACTERIAL ENDOTOXINS TEST (85): ▲It contains NMT 17.0 USP Endotoxin Units/mg of morphine sulfate. If labeled for intrathecal use, it contains NMT 14.29 USP Endotoxin Units/mg of morphine sulfate. ▲ (IRA 1-Sep-2019)
- PARTICULATE MATTER IN INJECTIONS (788): It meets the requirements.

# ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in sterile syringes for single-use in one patient only, protected from light. Store at controlled room temperature.
- BEYOND-USE DATE: In the absence of passing a sterility and endotoxin test, the storage conditions for High-Risk Level CSPs apply (see Pharmaceutical Compounding—Sterile Preparations (797), CSP Microbial Contamination Risk Levels, High-Risk Level CSPs). After successful completion of sterility and endotoxin testing, NMT 90 days after the date on which it was compounded when stored at controlled room temperature.

## Change to read:

- **LABELING:** Label it to indicate that it is for use in a single patient only. ALabel it to indicate that it is preservativefree. ▲ (IRA 1-Sep-2019) Label it to state the Beyond-Use Date.
- USP REFERENCE STANDARDS (11) **USP Morphine Sulfate RS**